See more : Papoutsanis S.A. (PAP.AT) Income Statement Analysis – Financial Results
Complete financial analysis of RemeGen Co., Ltd. (9995.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RemeGen Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Kuznetsky Bank Public joint stock company (KUZB.ME) Income Statement Analysis – Financial Results
- Midas Minerals Limited (MM1.AX) Income Statement Analysis – Financial Results
- Greatoo Intelligent Equipment Inc. (002031.SZ) Income Statement Analysis – Financial Results
- NALIN LEASE FINANCE LTD. (NLFL.BO) Income Statement Analysis – Financial Results
- HAKI Safety AB (publ) (HAKI-B.ST) Income Statement Analysis – Financial Results
RemeGen Co., Ltd. (9995.HK)
About RemeGen Co., Ltd.
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.08B | 767.78M | 1.42B | 0.00 | 0.00 | 11.32M |
| Cost of Revenue | 253.14M | 269.94M | 67.16M | 0.00 | 0.00 | 8.93M |
| Gross Profit | 822.99M | 497.84M | 1.36B | 0.00 | 0.00 | 2.39M |
| Gross Profit Ratio | 76.48% | 64.84% | 95.28% | 0.00% | 0.00% | 21.10% |
| Research & Development | 1.31B | 982.08M | 710.97M | 465.82M | 352.07M | 216.44M |
| General & Administrative | 313.67M | 272.54M | 219.84M | 217.62M | 32.78M | 9.37M |
| Selling & Marketing | 775.19M | 440.70M | 262.97M | 24.18M | 621.00K | 0.00 |
| SG&A | 1.09B | 713.24M | 482.81M | 241.80M | 33.40M | 9.37M |
| Other Expenses | -66.43M | -143.40M | -140.13M | -70.38M | 3.28M | 8.05M |
| Operating Expenses | 2.33B | 1.55B | 1.05B | 637.24M | 388.75M | 233.86M |
| Cost & Expenses | 2.58B | 1.82B | 1.12B | 637.24M | 388.75M | 242.79M |
| Interest Income | 28.14M | 61.54M | 43.35M | 1.66M | 147.00K | 21.00K |
| Interest Expense | 23.09M | 6.76M | 5.32M | 29.23M | 43.79M | 40.06M |
| Depreciation & Amortization | 240.28M | 186.37M | 120.47M | 49.89M | 41.00M | 22.64M |
| EBITDA | -1.25B | -805.70M | 402.05M | -661.56M | -343.85M | -208.72M |
| EBITDA Ratio | -115.96% | -105.07% | 28.26% | 0.00% | 0.00% | -1,843.62% |
| Operating Income | -1.50B | -993.07M | 281.92M | -668.55M | -386.63M | -231.36M |
| Operating Income Ratio | -139.53% | -129.34% | 19.80% | 0.00% | 0.00% | -2,043.59% |
| Total Other Income/Expenses | -9.70M | -5.76M | -26.83M | 9.85M | -43.66M | -38.48M |
| Income Before Tax | -1.51B | -998.83M | 276.26M | -697.82M | -430.28M | -269.95M |
| Income Before Tax Ratio | -140.43% | -130.09% | 19.40% | 0.00% | 0.00% | -2,384.49% |
| Income Tax Expense | 0.00 | -993.00K | 5.66M | 29.27M | 43.66M | -1.46M |
| Net Income | -1.51B | -997.84M | 276.26M | -727.09M | -473.94M | -268.49M |
| Net Income Ratio | -140.43% | -129.96% | 19.40% | 0.00% | 0.00% | -2,371.57% |
| EPS | -2.80 | -1.88 | 0.57 | -1.78 | -0.99 | -0.56 |
| EPS Diluted | -2.80 | -1.88 | 0.57 | -1.78 | -0.99 | -0.56 |
| Weighted Avg Shares Out | 539.72M | 530.12M | 487.44M | 408.15M | 478.36M | 478.36M |
| Weighted Avg Shares Out (Dil) | 539.72M | 531.15M | 487.44M | 408.15M | 478.36M | 478.36M |
Source: https://incomestatements.info
Category: Stock Reports